EA200400982A1 - Способы лечения пациентов, страдающих от нарушения движений - Google Patents

Способы лечения пациентов, страдающих от нарушения движений

Info

Publication number
EA200400982A1
EA200400982A1 EA200400982A EA200400982A EA200400982A1 EA 200400982 A1 EA200400982 A1 EA 200400982A1 EA 200400982 A EA200400982 A EA 200400982A EA 200400982 A EA200400982 A EA 200400982A EA 200400982 A1 EA200400982 A1 EA 200400982A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dopa
treatment
parkinson
disease
provides methods
Prior art date
Application number
EA200400982A
Other languages
English (en)
Inventor
Хироси Касе
Акихиса Мори
Ютака Ваки
Ютака Охсава
Акира Карасава
Есихиса Кувана
Original Assignee
Киова Хакко Когио Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200400982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Киова Хакко Когио Ко., Лтд. filed Critical Киова Хакко Когио Ко., Лтд.
Publication of EA200400982A1 publication Critical patent/EA200400982A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к способам лечения расстройств движения путем введения эффективного количества одного или более антагонистов аденозиновых Aрецепторов пациенту, нуждающемуся в этом. Данное изобретение представляет также способы снижения побочных эффектов L-ДОФА у пациентов, получающих терапию L-ДОФА при лечении болезни Паркинсона. Данное изобретение, кроме того, представляет способы и композиции для лечения пациентов с болезнью Паркинсона клинически субэффективными дозами L-ДОФА посредством сочетания лечения L-ДОФА с эффективным количеством одного или более антагонистов аденозиновых Aрецепторов (т.е. эффект снижения дозы L-ДОФА). Данное изобретение дополнительно представляет способы эффективного лечения болезни Паркинсона путем совместного введения по меньшей мере одного антагониста аденозиновых рецепторов, L-ДОФА и агониста дофамина, и/или ингибитора КОМТ, и/или ингибитора МАО. Данное изобретение, кроме того, представляет способы пролонгирования эффективного лечения болезни Паркинсона путем введения только антагониста аценозиновых Aрецепторов или вместе с агонистом дофамина, и/или ингибитором КОМТ, и/или ингибитором МАО без предшествующего или последующего введения L-ДОФА, отдаляя или устраняя начало двигательных осложнений, вызываемых L-ДОФА.Отчет о международном поиске был опубликован 2003.11.27.
EA200400982A 2002-01-28 2003-01-28 Способы лечения пациентов, страдающих от нарушения движений EA200400982A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35241302P 2002-01-28 2002-01-28
PCT/US2003/002658 WO2003063876A2 (en) 2002-01-28 2003-01-28 Methods of treating patients suffering from movement disorders

Publications (1)

Publication Number Publication Date
EA200400982A1 true EA200400982A1 (ru) 2004-12-30

Family

ID=27663091

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400982A EA200400982A1 (ru) 2002-01-28 2003-01-28 Способы лечения пациентов, страдающих от нарушения движений

Country Status (16)

Country Link
US (7) US20040198753A1 (ru)
EP (4) EP2942082B1 (ru)
JP (3) JP4376630B2 (ru)
KR (5) KR101098209B1 (ru)
CN (3) CN1646132A (ru)
AU (2) AU2003207734C1 (ru)
BR (1) BR0306919A (ru)
CA (2) CA2473864C (ru)
CO (1) CO5601022A2 (ru)
EA (1) EA200400982A1 (ru)
ES (2) ES2686123T3 (ru)
HU (2) HUE039348T2 (ru)
MX (1) MXPA04007299A (ru)
PT (2) PT2260850T (ru)
TR (1) TR201903603T4 (ru)
WO (1) WO2003063876A2 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EP2942082B1 (en) * 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd A2a receptor antogonists for use in the treatment of movement disorders
AU2003262860A1 (en) * 2002-08-30 2004-03-19 Kyowa Hakko Kogyo Co., Ltd. Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
AU2003304527B2 (en) * 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1824495A2 (en) * 2004-12-03 2007-08-29 ProteoSys AG Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ATE556712T1 (de) * 2005-06-07 2012-05-15 Kyowa Hakko Kirin Co Ltd A2a antagonisten zur behandlung von motorischen störungen
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US8802002B2 (en) 2006-12-28 2014-08-12 3M Innovative Properties Company Dimensionally stable bonded nonwoven fibrous webs
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
KR101742668B1 (ko) 2008-06-12 2017-06-01 골지 피티와이 리미티드 운동부족 및/또는 운동과잉 상태의 검출
CA2750265A1 (en) * 2009-01-20 2010-07-29 Marc Cantillon Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
US10258632B2 (en) * 2012-06-05 2019-04-16 International Stem Cell Corporation Method of prevention of neurological diseases
US9012640B2 (en) * 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CA2902756A1 (en) 2013-03-01 2014-09-04 Global Kinetics Corporation Pty Ltd System and method for assessing impulse control disorder
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
JP6381883B2 (ja) * 2013-10-04 2018-08-29 国立大学法人千葉大学 不随意運動の予防及び／又は治療組成物
US10736577B2 (en) 2014-03-03 2020-08-11 Global Kinetics Pty Ltd Method and system for assessing motion symptoms
WO2016148260A1 (ja) * 2015-03-17 2016-09-22 協和発酵キリン株式会社 医薬組成物
CA2988918A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
JP2019510088A (ja) * 2016-03-17 2019-04-11 ザ ジョンズ ホプキンス ユニバーシティーＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Ｐａｒｉｓのファルネシル化によってパーキンソン病を予防または治療する方法
US10973815B2 (en) 2016-03-31 2021-04-13 Versi Group, Llc Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease
US11246871B2 (en) 2016-07-15 2022-02-15 Northwestern University Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
WO2020189781A1 (ja) 2019-03-21 2020-09-24 協和キリン株式会社 パーキンソン病治療剤
EP3714888A1 (en) * 2019-03-25 2020-09-30 Assistance Publique - Hôpitaux De Paris Compounds for use in the treatment of adcy5-related dyskinesia
JP7382737B2 (ja) * 2019-05-13 2023-11-17 東和薬品株式会社 イストラデフィリン製剤
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176470T1 (de) 1990-10-18 1999-02-15 Kyowa Hakko Kogyo Kk Xanthinderivate
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2116967C (en) * 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
ATE208199T1 (de) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
DE69526822T2 (de) 1994-02-23 2003-01-23 Kyowa Hakko Kogyo Kk Xanthin-derivate
CA2284737C (en) 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
DE69815554T2 (de) 1998-01-05 2004-05-06 Eisai Co., Ltd. Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
BR9914040A (pt) 1998-09-22 2002-01-15 Kyowa Hakko Kogyo Kk Derivados de [1,2,4]triazolo[1,5-c]pirimidina e seu uso, medicamento, antagonista, agente para prevenir ou tratar doenças, bem como processo para prevenção ou tratamento de distúrbios
EP1177797A1 (en) 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Novel use
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
DK1221444T3 (da) 1999-07-02 2005-11-14 Eisai Co Ltd Kondenserede imidazolforbindelser og lægemidler mod diabetes mellitus
FR2796759B1 (fr) 1999-07-23 2001-11-02 Gemplus Card Int Minicarte a circuit integre et procede pour son obtention
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
HUP0300029A2 (en) 2000-02-25 2003-05-28 Hoffmann La Roche Adenosine receptor modulators, pharmaceutical compositions containing them and their use
US7189717B2 (en) 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
WO2001092264A1 (en) 2000-05-26 2001-12-06 Schering Corporation Adenosine a2a receptor antagonists
ATE385794T1 (de) 2000-06-21 2008-03-15 Hoffmann La Roche Benzothiazolderivate zur behandlung von alzheimer und parkinson
ATE444752T1 (de) 2000-08-11 2009-10-15 Eisai R&D Man Co Ltd 2-aminopyridin-verbindungen und ihre verwendung als medikamente
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
EP1379269B1 (en) * 2001-04-09 2009-03-04 Neurosearch A/S Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
EP2942082B1 (en) * 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd A2a receptor antogonists for use in the treatment of movement disorders
AU2003262860A1 (en) * 2002-08-30 2004-03-19 Kyowa Hakko Kogyo Co., Ltd. Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
DE602004029160D1 (ru) * 2003-06-10 2010-10-28 Kyowa Hakko Kirin Co Ltd
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US9238003B2 (en) * 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules

Also Published As

Publication number Publication date
KR20110010829A (ko) 2011-02-07
CN101822676A (zh) 2010-09-08
KR101098209B1 (ko) 2011-12-23
WO2003063876A3 (en) 2003-11-27
EP1469855A2 (en) 2004-10-27
US20120122897A1 (en) 2012-05-17
JP2012140461A (ja) 2012-07-26
WO2003063876A2 (en) 2003-08-07
EP2260850A2 (en) 2010-12-15
MXPA04007299A (es) 2004-10-29
CA2473864A1 (en) 2003-08-07
EP2260850A3 (en) 2013-11-13
US20060148827A1 (en) 2006-07-06
BR0306919A (pt) 2004-11-09
PT2260850T (pt) 2018-10-24
US20170196872A1 (en) 2017-07-13
CA2473864C (en) 2013-06-11
TR201903603T4 (tr) 2019-04-22
US20040198753A1 (en) 2004-10-07
EP2044940A3 (en) 2010-11-10
HUE043353T2 (hu) 2019-08-28
KR101166000B1 (ko) 2012-07-16
CN101543497A (zh) 2009-09-30
CO5601022A2 (es) 2006-01-31
AU2003207734B2 (en) 2008-02-21
EP2942082A3 (en) 2016-01-27
ES2686123T3 (es) 2018-10-16
ES2716404T3 (es) 2019-06-12
AU2003207734C1 (en) 2009-10-08
AU2008200611B2 (en) 2011-12-15
JP2009067807A (ja) 2009-04-02
US7727993B2 (en) 2010-06-01
PT2942082T (pt) 2019-06-06
EP2044940A2 (en) 2009-04-08
CA2813048A1 (en) 2003-08-07
US20140249166A1 (en) 2014-09-04
KR20100056569A (ko) 2010-05-27
US20180221377A1 (en) 2018-08-09
EP2942082B1 (en) 2019-03-06
JP5171556B2 (ja) 2013-03-27
JP5612016B2 (ja) 2014-10-22
HUE039348T2 (hu) 2018-12-28
KR20040077763A (ko) 2004-09-06
CN1646132A (zh) 2005-07-27
JP2005523898A (ja) 2005-08-11
JP4376630B2 (ja) 2009-12-02
US20060178379A1 (en) 2006-08-10
KR20150080013A (ko) 2015-07-08
EP2942082A2 (en) 2015-11-11
EP2260850B1 (en) 2018-07-04
US7727994B2 (en) 2010-06-01
AU2008200611A1 (en) 2008-03-06
KR20120103740A (ko) 2012-09-19

Similar Documents

Publication Publication Date Title
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
EA200501105A1 (ru) Фармацевтическая композиция
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
UA87980C2 (ru) Композиция для улучшения познания и памяти
JP6607852B2 (ja) 注意障害用および認知障害用ならびに神経変性障害に関連する認知症用の治療剤
JP2021138703A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ